Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034764 | 1.00 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL13040233 | 1.00 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL19544555 | 0.97 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL21440855 | 0.97 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL21440826 | 0.97 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL12118184 | 0.97 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL12641023 | 0.97 | MEN1 (0.41) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL15942666 | 0.93 | CES2 (0.40) | MEN1KMT2ACES2FAAHTSHR | |
| SCHEMBL21242896 | 0.92 | CES2 (0.42) | MEN1KMT2ACES2SMN1; SMN2FAAH | |
| SCHEMBL21242622 | 0.92 | CES2 (0.42) | MEN1KMT2ACES2SMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2795317-B1 | Composition for use in a method for cancer selection | GE HEALTHCARE LTD (GB) | 2018-05-30 | — | — | EP | disclosed |
| EP-2467365-B1 | RADIOIODINATION METHOD | GE HEALTHCARE LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| EP-1768708-B1 | N4 CHELATOR CONJUGATES | GE HEALTHCARE LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| EP-2509638-B1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-20160082136-A1 | METAL COMPLEXES AND FLUORINATION THEREOF | UNIVERSITY OF SOUTHAMPTON (GB) | 2016-03-24 | — | — | US | disclosed |
| US-9259496-B2 | Technetium labelled peptides | GE HEALTHCARE LIMITED (GB) | 2016-02-16 | — | — | US | disclosed |
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2016-01-28 | — | — | US | disclosed |
| US-9180213-B2 | Radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20150126708-A1 | RADIOFLUORINATION METHOD | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-8940274-B2 | Radioiodination method | GE HEALTHCARE LIMITED (GB) | 2015-01-27 | — | — | US | disclosed |
| US-20090203584-A1 | Peptide-based Compounds | GE HEALTHCARE LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-7521419-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2009-04-21 | — | — | US | disclosed |
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | SOLBAKKEN MAGNE | 2008-11-13 | — | — | US | disclosed |
| US-20080267881-A1 | IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2008-10-30 | — | — | US | disclosed |
| US-20080219921-A1 | Novel Technetium and Rhenium Complexes. | GE HEALTHCARE LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-7410943-B2 | Imaging agents | GE HEALTHCARE AS (NO) | 2008-08-12 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080095715-A1 | Peptide Based-Compounds | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
| US-20070297979-A1 | Pharmaceutical Compounds | GE HEALTHCARE AS (NO) | 2007-12-27 | — | — | US | disclosed |
| US-20070134155-A1 | Pharmaceutical compounds | AMERSHAM HEALTH AS (NO) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080219921-A1 | Novel Technetium and Rhenium Complexes. | IPO5, RAB35, TCOF1 | MEN1 10/4885KMT2A 4055/4885CES2 3605/4885 |
| US-20090203584-A1 | Peptide-based Compounds | ITGB3, ITGAV, SELPLG | MEN1 769/4885KMT2A 4471/4885CES2 4605/4885 |
| US-20070297979-A1 | Pharmaceutical Compounds | FURIN, ACE, PEPD | MEN1 225/4885KMT2A 1851/4885CES2 860/4885 |
| US-20080267881-A1 | IMAGING AGENTS | FLT1, FLT4, KDR | MEN1 2726/4885KMT2A 3554/4885CES2 3704/4885 |
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | MEN1 418/4885KMT2A 4017/4885CES2 1735/4885 |
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | MMP3, MMP1, MMP10 | MEN1 547/4885KMT2A 1649/4885CES2 499/4885 |
| US-20150126708-A1 | RADIOFLUORINATION METHOD | BTD, RABGGTB, PFAS | MEN1 1306/4885KMT2A 1510/4885CES2 775/4885 |
| US-20080095715-A1 | Peptide Based-Compounds | TEK, FLT4, FLT1 | MEN1 649/4885KMT2A 4418/4885CES2 4463/4885 |
| US-20070134155-A1 | Pharmaceutical compounds | NPPA, TNNT2, PCSK9 | MEN1 543/4885KMT2A 3631/4885CES2 1042/4885 |
| US-20160082136-A1 | METAL COMPLEXES AND FLUORINATION THEREOF | FOS, FGB, FOSB | MEN1 13/4885KMT2A 1784/4885CES2 3455/4885 |
| US-20080131368-A1 | N4 Chelator Conjugates | TTK, PIGK, HUNK | MEN1 44/4885KMT2A 1001/4885CES2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.